{"url_path":"/sec/pmvp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-218227-index.html","accession_number":"0001193125-26-218227","cik":"0001699382","ticker":"PMVP","issuer_name":"PMV Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1699382/0001193125-26-218227-index.html","primary_entity_key":"0001699382","primary_entity_name":"PMV Pharmaceuticals, Inc."},"word_count":369,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\nForm\n\nFile No.\n\nNumber\n\nFiling Date\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1699382/000119312520257820/d95525dex31.htm).\n\n8-K\n\n001-39539\n\n3.1\n\nSeptember 29, 2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1699382/000095017023020100/pmvp-ex3_3.htm).\n\n10-Q\n\n001-39539\n\n3.3\n\nMay 10, 2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1+\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](pmvp-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2+\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](pmvp-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1+†\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](pmvp-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.2+†\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](pmvp-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).\n\n \n\n \n\n \n\n \n\n \n\n† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n+ Filed herewith.\n\n25\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nPMV Pharmaceuticals, Inc.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ David H. Mack\n\nDavid H. Mack, Ph.D.\n\nPresident, Chief Executive Officer, and Director\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\nPMV Pharmaceuticals, Inc.\n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Michael Carulli\n\nMichael Carulli\n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n26"}